Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report), with a price target of $5.00.

As a refresher, the Mistral is the final Bugatti road car to use the incredible quad-turbo 8.0-liter W16 engine, alongside ...

We've tested 24 games on Intel's latest Lunar Lake laptop, to show how it stacks up against the previous generation Meteor ...

Bugatti has once again shattered records with the W16 Mistral, establishing a new top speed for open-top vehicles at an ...